GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Sihuan Pharmaceutical Holdings Group Ltd (HKSE:00460) » Definitions » Capex-to-Revenue

Sihuan Pharmaceutical Holdings Group (HKSE:00460) Capex-to-Revenue : 0.18 (As of Dec. 2023)


View and export this data going back to 2010. Start your Free Trial

What is Sihuan Pharmaceutical Holdings Group Capex-to-Revenue?

Capex-to-Revenue measures a company's investments in physical assets such as property, industrial buildings or equipment to its revenue.

Sihuan Pharmaceutical Holdings Group's Capital Expenditure for the six months ended in Dec. 2023 was HK$-155.59 Mil. Its Revenue for the six months ended in Dec. 2023 was HK$880.31 Mil.

Hence, Sihuan Pharmaceutical Holdings Group's Capex-to-Revenue for the six months ended in Dec. 2023 was 0.18.


Sihuan Pharmaceutical Holdings Group Capex-to-Revenue Historical Data

The historical data trend for Sihuan Pharmaceutical Holdings Group's Capex-to-Revenue can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Sihuan Pharmaceutical Holdings Group Capex-to-Revenue Chart

Sihuan Pharmaceutical Holdings Group Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Capex-to-Revenue
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.22 0.24 0.25 0.27 0.16

Sihuan Pharmaceutical Holdings Group Semi-Annual Data
Jun14 Dec14 Jun15 Dec15 Jun16 Dec16 Jun17 Dec17 Jun18 Dec18 Jun19 Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23
Capex-to-Revenue Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.38 0.24 0.35 0.15 0.18

Competitive Comparison of Sihuan Pharmaceutical Holdings Group's Capex-to-Revenue

For the Drug Manufacturers - Specialty & Generic subindustry, Sihuan Pharmaceutical Holdings Group's Capex-to-Revenue, along with its competitors' market caps and Capex-to-Revenue data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Sihuan Pharmaceutical Holdings Group's Capex-to-Revenue Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Sihuan Pharmaceutical Holdings Group's Capex-to-Revenue distribution charts can be found below:

* The bar in red indicates where Sihuan Pharmaceutical Holdings Group's Capex-to-Revenue falls into.



Sihuan Pharmaceutical Holdings Group Capex-to-Revenue Calculation

Sihuan Pharmaceutical Holdings Group's Capex-to-Revenue for the fiscal year that ended in Dec. 2023 is calculated as

Capex-to-Revenue=- Capital Expenditure / Revenue
=- (-323.122) / 2035.018
=0.16

Sihuan Pharmaceutical Holdings Group's Capex-to-Revenue for the quarter that ended in Dec. 2023 is calculated as

Capex-to-Revenue=- Capital Expenditure / Revenue
=- (-155.586) / 880.31
=0.18

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Sihuan Pharmaceutical Holdings Group  (HKSE:00460) Capex-to-Revenue Explanation

Capex-to-Revenue measures a company's investments in physical assets such as property, industrial buildings or equipment to its revenue. The ratio shows how aggressively the company reinvests its revenue back into productive assets. However, a high ratio potentially indicates that the company has invested too much in innovation and infrastructure, taking up funds that could be used to boost productivity and increase revenue. Therefore, a high Capex to Revenue Ratio could be a positive or a negative sign depending on how effectively a company converts those investments into future earnings.


Sihuan Pharmaceutical Holdings Group Capex-to-Revenue Related Terms

Thank you for viewing the detailed overview of Sihuan Pharmaceutical Holdings Group's Capex-to-Revenue provided by GuruFocus.com. Please click on the following links to see related term pages.


Sihuan Pharmaceutical Holdings Group (HKSE:00460) Business Description

Traded in Other Exchanges
Address
Zhubang 2000 Business Centre, 22nd Floor, Building 4, West Balizhuang, Chaoyang District, Beijing, CHN, 100025
Sihuan Pharmaceutical Holdings Group Ltd is an investment holding company. Along with its subsidiaries, the company is engaged in the research & development and the manufacture & sale of pharmaceutical products. Its portfolio comprises products for diseases related to the cardio-cerebral vascular (CCV) system, Digestive System, Anti-Infective, metabolism, Respiratory, Neurology, and Others. The group has three reportable segments: the medical aesthetic products segment including the filling, shaping, supporting, supplementing, optoelectronic device, body sculpturing, skincare, and others to provide non- or minimally invasive medical aesthetics comprehensive solutions; the innovative medicine and other medicine segments; and the generic medicine segment.
Executives
Che Fengsheng 2201 Interest of corporation controlled by you
Guo Weicheng 2201 Interest of corporation controlled by you
Meng Xianhui 2201 Interest of corporation controlled by you
Zhang Jionglong 2201 Interest of corporation controlled by you
Mingyao Capital Limited 2401 A concert party to an agreement to buy shares
Network Victory Limited 2401 A concert party to an agreement to buy shares
Proper Process International Limited 2401 A concert party to an agreement to buy shares
Successmax Global Holdings Limited 2101 Beneficial owner
Victory Faith International Limited 2401 A concert party to an agreement to buy shares
Ubs Tc (jersey) Ltd 2301 Trustee
Ubs Trustees (cayman) Ltd. 2301 Trustee
Smart Top Overseas Limited 2501 Other
Plenty Gold Enterprises Limited 2307 Founder of a discretionary trust who can infl

Sihuan Pharmaceutical Holdings Group (HKSE:00460) Headlines

No Headlines